Welcome and thank you for joining Oaktree Specialty Lending Corporation Second Fiscal Quarter 2021 Conference Call. Today's conference call is being recorded. At this time, all participants are in a listen-only mode. Now I would like to introduce Michael Mosticchio of Investor Relations, who will host today's conference call. Mr.

Mosticchio, you may begin..

Thank you, operator, and welcome to Oaktree Specialty Lending Corporation's second fiscal quarter conference call. Our earnings release, which we issued this morning, and the accompanying slide presentation can be accessed on the Investors section of our website at oaktreespecialtylending.com..

Thank you, Mike, and welcome, everyone. We appreciate your interest in and support of OCSL, and we hope everyone listening as well. We continued to generate momentum in the second quarter with earnings, origination activity and credit quality all strong. We reported NAV per share of $7.09, up 4% from the prior quarter.

The increase reflected both continuing market spread tightening and price appreciation on certain liquid debt investments during the quarter. As with last quarter, our NAV continues to exceed its pre-COVID high and is up more than 7% and from the end of calendar 2019. We continue to produce steady strong results.

Adjusted net investment income per share, which excludes the impact of asset acquisition accounting related to the merger with Oaktree Strategic Income Corporation was $0.14, up slightly from the prior quarter.

Based on our consistent performance and confidence in the potential to further improve earnings, our Board increased our quarterly dividend by 8% to $0.13 per share the fourth consecutive quarterly increase. This also marked a 37% increase from a year earlier.

We continue to actively identify attractive new deals, during the quarter, and excluding the assets we acquired as part of the OCSI merger, we originated $318 million of new investment commitments. Of these 80% were first lien loans..

Thanks, Matt, and good morning, everyone. The credit and equity markets continue to advance along with declining unemployment, an improving economy and forecast for strong GDP growth in the second half of 2021.

The vaccine rollout programs, while varied by country, have proven successful to date overall in the United States and other developed countries, adding to optimism. We share in the confidence and yet, ours is cautious optimism.

Exceptional fiscal and monetary stimulus has supported the recovery and helped fuel investor confidence, liquidity and the availability of credit.

We believe equity valuations already reflect expectations for strong economic growth and therefore, may be inflated as the ultimate success of vaccinations and corresponding GDP expansion still remain uncertain.

Mindful of that uncertainty, we continue to approach new investments defensively, guarding against the downside in our investments and securing appropriate compensation for risk. All of that noted, we are actively investing in generating strong risk-adjusted returns for our shareholders.

We are drawing upon the full breadth of Oaktree's scale and resources to invest across multiple markets with a diversified group of issuers.

We are further building the portfolio with investments in consistently performing companies and in sectors that present relatively low risk, notably including those that proved resilient throughout the pandemic from life sciences to application software.

We are also lending to businesses that are not easily underwritten via traditional cash flow based methodologies, and we continue to carefully study the rescue lending landscape, an area in which we have found appealing opportunities.

We also continue to pursue unique opportunities where competition is limited, leveraging Oaktree's ability to negotiate and structure customized private deals that provide downside risk management by mitigating specific risks of the issuer. Now turning to the overall portfolio.

At the end of the second quarter, the portfolio was well diversified with $2.3 billion at fair value across 137 companies. The portfolio grew as a result of the $504 million of assets we acquired from OCSI and net new investment fundings.

86% of the portfolio was invested in senior secured loans, our median portfolio company EBITDA at March 31 was approximately $100 million as we continue to focus on lending to larger, more diversified businesses..

Thank you, Armen. Good morning, everyone. Before getting into the discussion of the income statement, I would like to discuss the GAAP accounting that is related to our merger with OCSI because of its unique treatment of asset valuations.

Although the merger was structured as a NAV or NAV exchange under GAAP, the merger was accounted for using the asset acquisition method. Under this framework, the fair value of the consideration paid by OCSL to acquire OCSI was based on the number of OCSL shares issued and stock price immediately prior to the merger close..

Thank you, Mel. Over the last three quarters, we have generated an improved return on equity compared to prior year quarters, which is evidence that our efforts in this area are paying off. Operating results have been strong. Following our robust origination activity and credit quality continues to be excellent.

The defensive repositioning that we have carried out since 2017 has largely been completed, and our pipeline of potential transactions remain solid. As a result of this strong performance, we have increased the dividend from $0.095 to $0.13 per share in the past year.

That said, we continue to believe that OCSL is well positioned to grow ROE further from here. First, we remain focused on positioning the portfolio for an improved yield by rotating out of lower-yielding investments and into higher-yielding proprietary loans.

We continue to make good progress here in the second quarter exiting $49 million of these types of investments. As of quarter end, $163 million of senior secured loans priced at or below LIBOR plus 4.5% remained in the portfolio including approximately $102 million of loans that we acquired in the OCSI merger.

Our new investments during the quarter came in at an average yield of 8.2%. So there is continued upside to be realized time. Another opportunity for us to increase ROE is by deploying more leverage at the portfolio level. As of March 31, we are operating just below the low end of our long-term target of 0.85 to 1.0 times.

And so we would expect to continue to enhance returns as we make incremental investments and deploy higher leverage. However, we will only grow the portfolio as we find opportunities that are consistent with our investment approach that we believe offer an attractive risk reward.

We also have the opportunity to further optimize both of our joint ventures. We can accomplish this by not only judiciously increasing leverage of the JV but also by rotating out of lower-yielding investments into higher-yielding ones. We believe that disciplined growth of the JVs will also be accretive to ROE over time.

Finally, we expect to realize synergies from our recent merger with OCSI, which we anticipate will benefit our ROE going forward. These include approximately $2 million of annual expense savings and the waiver of $750,000 per quarter in management fees for eight quarters.

Further, as I mentioned earlier, we are working on streamlining our capital structure to reduce our overall cost of capital while enhancing our funding flexibility. In conclusion, we are very pleased with our strong second quarter results.

We are happy to have completed the seamless merger with OCSI as we have achieved further scale portfolio diversity and expected earnings accretion.

We are excited about our future and remain optimistic that we will continue to identify new attractive risk-adjusted investment opportunities, which will allow us to deliver improved returns to our shareholders. Thank you for joining us on today's call and for your continued interest in OCSL. With that, we're happy to take your questions.

Operator, please open the lines..

And the first question will come from Devin Ryan with JMP Securities. Please go ahead.

Maybe just to start off here with kind of market question. I heard the commentary around where valuations are and maybe how optimist on the implied outlook is. And so I always appreciate hearing your views on what you're seeing in the market.

And if possible, just good to be -- good to get some deration between what you're seeing on the sponsor side versus the non sponsored side, if there is any? And then just where kind of some of those more attractive opportunities are today, just given kind of that backdrop you started with..

Thanks for the question, Devin. This is Armen. So I've mentioned this on prior calls, but when we look at the opportunity set, we look at fundamentals, technicals and valuation so when we look at the fundamentals, I would say, sequentially, we've had three quarters of improved performance in most businesses in the U.S.

and globally quarter-over-quarter. A lot of companies in the energy space even have had really solid performance in the last couple of quarters with rising oil prices. So the fundamentals, I would say, are trending in the right direction but not yet reflective of a complete recovery from the pandemic.

One of the issues still holding back the fundamentals is a -- it's actually two issues. One is a labor shortage, especially of skilled labor in the United States. And then the second is, there have been supply chain disruptions over the last few quarters. And so getting certain types of products has been a little bit of a challenge to some businesses.

We see it, especially in luxury products. We see it in chips. There's been a lot of talk about a global chip shortage. So the fundamentals are certainly heading in the right direction, but still not to post pandemic levels.

In terms of valuation, with the tremendous amount of stimulus that's been pumped into the economy, valuations have gotten really high, generally.

And so there was a little bit of a pullback a couple of months ago in valuations of some of the higher flying tech companies on the stock exchange, really commensurate with a rising interest rate environment. The 10-year treasury touched just above 1.7% and has come back down.

But that little moment there was a little bit of a sign of potential times to come, where the conditions that we're seeing in the economy today could give rise to inflation, could give rise to higher interest rates.

And therefore, our expectation would be that very high multiple valuation companies and stocks will potentially have some downside if we do see that rising rate environment play through on the heels of what's likely to be at least a transitory inflationary backdrop. So we are very cautious about valuations.

I think a lot of private equity firms are also cautious about valuations. And we're seeing some deal flow on the LBO side, for sure, but I think folks are kind of wondering what happens with valuations if the rising rate environment does kick in.

In terms of technicals, there's a lot of capital out there, both in the public markets as well as the private debt markets. And we are seeing the impact of that capital in terms of the recent deal flow that's been making it in the market recent has been definitely in 2021, not prior to that.

And I would say that, generally speaking, legal and economic terms have deteriorated over the last couple of months because there are several managers out there that have raised very large funds that are looking for deals and the most kind of consistent way of sourcing that deal flow is through the LBO sponsor back market and by providing large solutions, large loans in support of those LBOs at terms that are tighter and more flexible from a legal perspective than they were even pre pandemic.

So we are very cautious about the quality of the deal flow we're seeing on the LBO sponsor side. And we are participating in it, but I would say that we are finding better opportunity on the nonsponsor side these days. As I've said on prior calls, it's very hard to predict the timing of our non-sponsor deal activity.

But our pipeline today is largely composed of non-sponsor deals, really leveraging the Oaktree platform and some of the -- off the center of the fairway type of deal flow that we see as an institution. So we'll -- it will be balanced going forward. We'll try to -- we'll try to find some good LBO opportunities as well.

But I would say that the trend in terms of legal and economic terms on that side of our origination is heading or has had towards a less attractive position..

As a follow-up, the remaining $164 million of noncore investments in the portfolio. I'd imagine those are primarily less liquid. At this point and the liquid positions were sold off leading into or following the merger? Or I just want to make sure that's a fair assessment.

And then whether there's any transparency kind of into a time line for rotation there?.

Yes. I think your statement is correct. They are less liquid. It's challenging to determine the timing of an exit, but you should know that we are very focused on exiting those positions. I think the good news is with the recovery in the economy, those positions are their valuations have improved since the bottom.

So we would hope and expect that we will see some resolution over the coming quarters, but it's -- I wouldn't be able to provide forward-looking guidance on what that could look like..

Yes. And Devin, it's Matt. What our strategy with the noncore from the beginning was rather than to do kind of a large portfolio sale at a relatively low price to work each situation independently and try to maximize value, which I think we've done a good job of and we'll continue to do that.

To Armen's point, every day, every quarter, we're exiting -- working on exiting investments. We're exiting the noncore investments. And so that's been good. The -- some of the investments have been convert up materially as last quarter, given the performance of the company.

So we're focused on it every day, to Armen’s point, it's tough to pick a time line, but it is something that we're -- we want to keep making progress towards every quarter..

The next question will be from Kyle Joseph with Jefferies. Please go ahead..

Congrats on the good quarter and getting the merger across the finish line.

Repayments are obviously difficult to predict, but just can you give us a sense, given you talked about a hot market and just your expectations for repayments this year versus maybe last as a benchmark?.

Yes, Kyle, it's a good question, but it requires a little bit of a crystal ball. We haven't -- we haven't been hit with a lot of repayments, but we expect that just given the nature of some of our origination that some of our portfolio companies are good spec candidates, some of our portfolio companies or good refi candidates on the LBO side.

So I wouldn't be surprised if we see elevated repayments this calendar year versus last year. But I wouldn't be able to dimensionalize the size of that, unfortunately..

And then, obviously, your credit has been very strong, looking at your NPAS.

But just in terms of the underlying portfolio performance, can you give us a sense for whether it's revenue or EBITDA growth in the first quarter and how that compared to the fourth quarter and kind of the outlook here as we have lapped some of the more difficult comps and kind of given that, what your expectations are for credit for the remainder of the year?.

Sure. So I would say that in the third and fourth quarter of last year, I'm talking calendar quarter last year, most companies had revenues down 5% to 25%. And I'm saying just broad economically. And I think our portfolio is in that range as well.

However, I think very good managers of very strong businesses took out a lot of cost during that time frame as well. And we're able to run with a cash flow generation profile that resulted in them not having any sort of issues around restructurings. So it was more of a cost containment story in the back half of last year.

In the first quarter, I think that cost containment story has continued to play through in that they have not and that costs are still pretty low. They haven't taken -- they don't seem to have taken out additional costs in the first quarter, but the revenue line has certainly picked up sequentially.

So when you compare first quarter -- first calendar quarter revenues this year, versus third and fourth quarter last year, it's higher. It's higher probably by ballparking 4% to 10%, 4% to 8% in that range.

And so if you combine that type of revenue growth with pretty good cost containment, you're seeing nice EBITDA growth as well on a sequential basis. On a year-over-year basis, I would say most businesses at best or flat, first calendar quarter 21 to first calendar quarter but most of them, frankly, are still down from where they were pre pandemic.

So it's an important distinction because valuation multiples of companies, terms on new loans are all at pre pandemic types. Meanwhile, the performance of businesses is not quite where it was pre-pandemic.

Is that helpful?.

And the next question will be from Bryce Rowe with Hubby Group. Please go ahead..

I wanted to ask about kind of the comments around the cautious optimism from an outlook perspective and how you think about where you want to be in terms of your balance sheet leverage target on the low end, middle part of it or towards the higher end of that balance sheet leverage target, given the outlook..

Thanks for the question, Bryce. So going into March of last year, we were running at or below our leverage target. And that really allowed us to get pretty opportunistic in our investments with rescue loans with public market trading activities in a variety of different asset classes.

And that was really because we were entering that period, feeling that terms and conditions in the private credit markets broadly were just not as attractive as we would like them to be. We're still finding pretty attractive investments in the private credit markets right now, especially in the nonsponsor space.

But I would expect, given our tone of cautious optimism, will be in the -- probably closer to the low end of our target range. Barring any sort of surprises to the upside in terms of non-sponsor deal flow that we may be able to find that we think is mispriced risk. So we're always looking for those types of idiosyncratic opportunities.

They could present themselves even when the markets are pretty strong and some of the harder to understand or harder to underwrite businesses. We do still see a lot of deal flow in our life sciences area and some of the other areas that are outside of the LBO sponsor activity area.

So if we did see some surprises to the upside on our origination on the nonsponsor side, I could see us trending towards the middle part of our range. I don't think that we'll be on the high end of our range in the -- in the next couple of months. It's hard to predict beyond what -- what I see in our pipeline today, though..

Yes, it's Matt. Just to sure everyone's benefit. Our target range is 0.85 to 1. And that's -- we're still very comfortable with that range..

Let's see, I wanted to ask about the liability structure, the capital structure, obviously, it's been a point of emphasis over the last couple of quarters with the pending transaction with OCSI. Now that that's done, obviously, you're making some progress in having remixed some of the liability structure already.

Just kind of curious how you're thinking about the one remaining SPV there now and how you might try to take advantage -- further take advantage of what we're seeing in the unsecured debt markets right now..

Thanks, Bryce, it's Matt. I appreciate the question. So as you referenced, we like and had a very balanced capital structure. And also, as you referenced, we amended and extended our revolving credit facility and got a very, very positive reception from both our existing banks as well as new banks.

We're able to do some important and attractive things on the pricing and the borrowing base, et cetera. So that was one piece of it.

And then as you referenced, the -- we retired one of our SED facilities that was very expensive at LIBOR plus 2.65 versus our revolving facility, which is labor plus 200 in the existing SD facility, we still have in place, that's much more attractively priced than the DB facility that we repaid. So we'll -- we like that and plan to keep that.

And then kind of to your point, we continue to be thoughtful about our capital structure and a year plus ago, we did a very successful unsecured bond deal. So that's obviously an option that we consider going forward.

But yes, I think we've made good progress to date, and we'll keep being thoughtful about it and be in a position like we were a year ago to take advantage of any opportunities in the market to invest attractively..

And maybe one more for Mel. Mel, you mentioned the Kemper JV possibly paying a dividend here in the -- I guess your third fiscal quarter.

Any guidance around what that dividend might look like?.

Can't give you guidance on the amount of the dividend at this time. We're going to monitor it over the next quarter and consult with our partner there. So more to come on that..

And the next question is from Ryan Lynch with KBW. Please go ahead..

I just wondered, how do you guys kind of balance your guys' target of increasing your return on equity, would you talk about kind of increasing leverage levels is one of the main components of that with sort of the cautious -- the more cautious outlook for deploying capital? Because it just seems to me, if you guys aren't super excited about the sponsored lending environment, that certainly risk ricks, the level of deals you guys are going to be putting on your books? And then you guys also have the other goals of divesting some of the lower-yielding investments, actually in some of the noncore investments, plus the general market just has a lot of strength in the BSL market.

That's going to provide, I think, a lot of -- and it probably already has had some refinancing risks out there that could have some portfolio repayments.

So how are you balancing that of wanting to add on additional leverage to increase the ROE, but it sounds like there could be at least from everything that I've heard, it sounds like it may be tough to actually add net-net growth over the coming quarters?.

Yes. It's a good question, Ryan. This is Armen. So we have a variety of levers we could pull to help drive ROE. We do have part of our portfolio and low-yielding assets that are publicly traded that are a source of cash. A portion of the OCSI portfolio that was merged into OCSL is such a source.

So that's one area where if we just rotate it from the lower yielding, the lower-yielding nature of some of those assets into even just average yielding, LBO and non-sponsor deal flow that we're seeing that will be accretive to the ROE without even increasing leverage.

There is the leverage opportunity and to increase leverage, what I would just say is, for us to drive up leverage to the top end of our target or even through the top end of our target to do LBO deals, specifically first lien LBOs now are pricing at LIBOR plus 475 to 500 in the middle market.

These are the more traditional first lien, pretty low levered. For us, that's not an optimal use of increasing leverage. We'd rather increase leverage in connection with originating 8%, 9%, 10% type of paper in the nonsponsor area.

And we've talked about this in the past, but just being part of Oaktree, we do see a lot of deal flow that traditional sponsor chasing managers typically don't see or don't spend the time to try to originate. And that's where we are able to drive some incremental growth in ROE through high higher-yielding opportunities.

And getting paid an attractive return for what we assess as being lower risk than other situations. And n incorporated is a good example of a deal that we did in the quarter, I mean, this is a public company.

We -- the investment came actually through our special situations group initially that was potentially discussing a junior equity or debt solution for the company. It changed into a senior solution for us with less than three turns of leverage and a requirement that the company go and raise a preferred equity beneath us.

So we got paid a nice return that was wide of LBO sponsor loans, especially if the -- if the company was under three turns of leverage, in a sponsor deal, that would be LIBOR plus 450 to 500, and we were paid close to LIBOR plus 700 with OID and fees.

So that's kind of a long way of saying that we just have to get more creative on the origination side rather than relying on the market, the private credit market delivering us the beta of the market. We really are looking for alpha opportunities. We're finding alpha opportunities.

In 2020, when the economy was in disarray, we were able to find a lot in the rescue lending area. And we were -- and even though that particular opportunity has waned on a broad basis in terms of across industries, it is still there in pockets.

And it could be in the energy space, it could be in other areas that we're still seeing some pretty nice deal flow or potential deal flow. In the situational lending area, these are companies that are hard to understand, hard to underwrite, we're seeing a fair bit of deal flow there.

And they don't fit nicely in the underwriting standards of other managers because there isn't fresh equity capital coming in or there isn't a clean sort of debt-to-EBITDA story. But as a result, we're able to get very tight legal terms and wide economic terms.

So we're spending a lot of our time on the sides of the fairway rather than in the center of the fairway, and we're finding the ability to still continue to net-net, originate on a positive basis. So rather than contracting the portfolio, we're still expanding. And the first calendar quarter this year, you saw that. We did expand the portfolio.

Even though a lot of the competitive dynamics that I had mentioned earlier, were still in play this quarter. So it's really being part of Oaktree that is the competitive advantage for us, and we'll continue to utilize our competitive advantage to drive ROE higher without having to simply rely on higher leverage to deliver that ROE.

Just one last point before I get off my soapbox. Last year, higher levered or higher leverage proved to be a disadvantage because as that -- as the economy kind of tumbled, leverage providers did pull back, and we did see folks have to issue equity at discounts to NAV.

And we saw a lot of managers, whether BDC or non BDC, pull back from the market because they were unsure about what sort of issues they were going to have in their portfolio with their leverage providers, et cetera.

And we didn't -- we were extremely active in trading, extremely active in originations, and we think we could strike a balance between now and that next dislocation to still be to still go on the offensive when that happens as well..

Yes. And Ryan this Matt, just picking up on that last point, and we'd agree with you that I did kind of get to your comments. It is hard. It's hard to originate, but that's okay.

And one of the things that I think has happened and Armen hit it a little bit on the last comment, but going in the pandemic, post pandemic we were very, very active during the pandemic across Oaktree and particularly in OCSL.

And I think that really helped increase our market share, our mind share, our kind of conversations, both sponsor and nonsponsor. And it's definitely created a tailwind in terms of just our presence in the marketplace and direct lending. And I think that really helped us and will continue to. Yes..

And just to be clear, this is Armen again. Just to be clear. On the LBO side, we will do some LBO deals this year, next quarter, the following quarter. So don't get me wrong. What I what I would like to point out though is that our hit rate will be lower. We will see a lot more deals and our look to book will be just lower.

And that's okay, and we're going to fill what we don't do on the LBO side with what we are able to find on the nonsponsor side..

That's really helpful. Color and really good commentary on how you guys are thinking about the space. And I can certainly appreciate, and I think investors should also appreciate that you all are looking to be direct lenders that are generating -- trying to generate alpha versus just being asset gatherers, and I think that's a really wise approach.

That's all I had today. So I appreciate the time this morning..

The next question is from Melissa Wedel with JPMorgan. Please go ahead..

Today. One of the things that jumped out in going through your slide deck was the number of new companies that you allocated capital to during the March quarter.

What stood out about that is that we seem to be hearing from a lot of teams that there's increased confidence or increased comfort in deploying capital to existing portfolio companies, companies that you been working with already, and you can see growing out of the environment.

I'm curious if there's anything in particular that drove this high allocation to 18 new companies in the portfolio? And is that indicative of sort of a return to normal on your due diligence process for new companies?.

Yes. Thanks for the question, Melissa. There wasn't any sort of macro theme oriented influence on our origination in the quarter. We just, frankly, saw a lot of deal flow in a variety of different areas and that we were able to structure appropriately.

We did do some LBO sponsor deals in the quarter for sure, but we also were very active tapping the Oaktree platform for a lot of other deals that were proprietary in nature, still -- or situations that we were negotiating in the fourth quarter that got funded in the first quarter, so still suffering from a little bit of dislocation in some of the traditional lending areas that were -- that ordinarily would have supported that type of issue.

We did do some real estate deals, for example, in the last couple of quarters that we're very well structured, very well priced, really because the dislocation in the real estate market went a little bit longer than the dislocation in the corporate credit markets.

So it wasn't -- our origination wasn't really with a macro view to sort of chase recovery. It was that we were able to find well-structured well-priced deals and not really in tremendously cyclical businesses either. So we feel really good about what it is.

But it's -- but Oaktree generally and certainly on is a bottoms-up fundamental credit by credit analytical shop. It is we don't really take a macro view on really anything we do. We don't really predict macro, and we certainly don't have the macro drive our risk taking.

We certainly acknowledge what the macro environment is and feed that into our underwriting to assess the risks. But we don't say, hey, the sun is shining, let's make hay, and let's just go originate as broadly and as actively as we can because you really can't lose money in this environment. That to us is a recipe for disaster..

And the next question is from Jordan Latin with Wells Fargo Securities. Please go ahead. .

It's an O’Shea on for Jordan this afternoon. I just want to try to squeeze a little bit more out of the leverage topic, which was extensive and helpful.

Can you -- just putting that all together, I'm summarizing it as your comparatively low leverage target is a function of the ability to find quality deals even with -- even those deals being higher spread, and that juxtaposes a bit versus the space, which most of your peers will lower leverage when higher-yielding arenas and raise leverage and lower-yielding strategies.

So it does -- I guess, first part of the question, it does sound a bit -- quite a bit different for you in your approach.

Is that fair to say that your target is a function of the dearth of attractive non-sponsor and specialty deals and so forth?.

Yes. I would say it's a dearth of opportunity, but it's certainly harder to find in a predictable and consistent way the non-sponsor deal flow versus sponsored deal flow. I mean for -- I equate the thinking around originating in response area to what an insurance underwriter does.

When an insurance company says, "I want to have more -- I want to have more premium under management under -- in the business, they loosen their underwriting terms and they accept more and they're able to turn it on and turn it off with pretty controllable regularity. And it's -- that's a little bit of an analogy to the sponsor business.

It's -- we see a lot of deal flow on the sponsor side, and we could easily turn it up, and we could easily turn up leverage and have the leverage manufacture of the returns.

But it also creates an additional area of risk and we don't think it's prudent at all times to dial up return when it's hard to -- when you have to work harder to find deals, low, it doesn't mean that you could just resort to just dialing up leverage and making the leverage work for you. I think we will be within our target of our leverage target.

I do think that we have a lot of deals in our non-sponsor pipeline that will show the power of the Oaktree platform over the coming quarters. I think we've already shown the power of the Oaktree platform over the last few quarters.

So yes, I mean, I think that if we were a more traditional manager that was only doing leverage buyout activity and was maximizing leverage as a result and more focused on accumulating market share in the LBO area, yes, we would run leverage higher than we run today.

It's because we do non-sponsor deals, which are harder to time but higher-yielding and more attractive from a legal perspective that we run leverage lower..

Yes. So totally understood. And I think -- and I think your dialogue with Ryan suggested that you're working to grow that funnel. I don't know if it's more -- create more access to non-sponsor or go wider and do things like life sciences and real estate, as you mentioned with others.

But regardless, like that should be one would think that, that's all becoming more difficult as well with the growth of private markets and the institutionalization and maturation and so forth. I at least would imagine that these deals are becoming more and more shape and more and more competed on.

So waiting for it to come back to you to grow the book to an improved ROE, it seems like at least a plan that would require a lot of patients so I would you say, are you being patients to see more of those deals? Or is there sort of an active game plan to find attractive arenas that would compel you to grow into a normal, let's say, $120 million debt-to-equity ratio..

Well, we have an active game plan to originate deal flow. We're definitely not waiting around for somebody to throw something over the transom to us. So -- but I hope that's not the deduction that anybody receives from any of my commentary. I mean, the -- yes, it is hard to find the deal flow.

I wouldn't say that it's getting more competitive, actually, just because these are harder to understand situations.

We don't find ourselves getting a term sheet from an intermediary saying, "Hey, will you hit this on this non-sponsor deal, it's literally a company sponsor, family office, management team coming to us and saying, "Hey, I need a strategic partner to help me grow, I mean a transitional period in my company.

I need someone that's going to take the time to understand how to -- or what I need and to structure something that works in size. And we find that it isn't a highly competitive market there, but it takes time. It takes time. It takes -- or people who are on the ground originating.

It takes time of people around Oaktree across all strategies at Oaktree, saying, this isn't a good fit here, but it might be a good fit over -- in another area of the firm that I work in. So we benefit from having many more people than what is kind of on the page, helping us originate in this nontraditional area.

So it is not a passive activity for us. It is not a wait and see what advisers throw our way. We're finding a lot of deal flow, and we are actually also leveraging the Brookfield relationship as well to drive some deal flow at that is proprietary. So will we get to 1.2 times or above our range? It's possible.

But I think we're focusing on walking before we run. I mean we have lower-yielding assets that we could sell. We have noncore assets that we're looking to exit. We have a lot of room between the 0.84 turns of leverage we're at right now versus north of one:one to get through before we talk about going through our leverage target.

So I don't know if I'm answering your question or not, but it's a blocking and tackling exercise every quarter. And we have a lot of folks in place, constantly looking for deal flow, and we're able to originate in tough environments..

And I do think if you go to Pages 5 and 6 in our investor deck, I think we do lay out some good data in terms of originations, both by quarter and then from the leasing quarter to the month.

So you can see for the current quarter, it's a very competitive environment, right? We originated on the private side, 2.5, the public side, 63 and then the second year 10. And the quarter before that, those numbers 81, 84, 22.

So I think that gives you a good sense of quarter-by-quarter, month-by-month and most recent month, which is obviously a competitive market that we are finding attractive things to invest in.

It's -- but we're going to be thoughtful and prudent and do all the things that leveraging the kind of the Oaktree platform, our market are mind share gains over the last year to do that..

Ladies and gentlemen, this concludes our question-and-answer session. I would like to turn the conference back over to Michael Mosticchio for any closing remarks..

Great. Thanks, Chad, and thank you all for joining us on today's earnings conference call. A replay of this call will be available for 30 days on OCSL's website in the Investors section or by dialing (877) 344-7529 for U.S. callers or 1(412) 317-0088 for non-U.S.

callers with the replay access code 10153868, beginning approximately 1 hour after this broadcast..

Thank you, sir. The conference has now concluded. Thank you for attending today's presentation. You may now disconnect..